Literature DB >> 25522926

Tumor-associated inflammation as a potential prognostic tool in BRCA1/2-associated breast cancer.

Victorien M T van Verschuer1, Maartje J Hooning2, Radka D van Baare-Georgieva3, Antoinette Hollestelle2, Anne M Timmermans2, Linetta B Koppert4, Leon C Verhoog5, John W M Martens6, Caroline Seynaeve2, Carolien H M van Deurzen7.   

Abstract

The prognosis of BRCA1/2-associated breast cancer partly depends on histologic characteristics. Most of these breast cancers, however, are poorly differentiated. BRCA1-associated cancers are mainly negative for estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2. Consequently, the use of these histologic features for risk stratification in BRCA1/2 breast cancer is limited. We assessed the prognostic value of additional histologic features, including tumor-associated inflammation and tumor-associated stroma in BRCA1/2 breast cancer patients. From the Rotterdam Family Cancer Clinic database, we collected demographics, tumor characteristics, and follow-up data from female BRCA1/2 breast cancer patients. Tumor samples were centrally reviewed including histologic subtype, differentiation grade, tumor-associated inflammation density, amount of tumor-associated stroma, and intratumor necrosis. The impact of these factors on recurrence-free survival (RFS) was evaluated using univariate and multivariate Cox regression, adjusted for established prognostic features and year of diagnosis. We included 138 BRCA1 and 37 BRCA2 breast cancer patients. Median follow-up after diagnosis was 9.7 years. Independent prognostic factors for RFS were tumor size (hazard ratio [HR], 2.47 for >2 versus ≤2 cm; 95% confidence interval [95% CI], 1.10-5.57), tumor-associated inflammation (HR, 0.18 for moderate/marked versus absent/mild; 95% CI, 0.05-0.61), and intratumor necrosis (HR, 2.60 for presence versus absence; 95% CI, 1.12-6.05). Established prognostic factors as nodal status and differentiation grade were not significantly related to RFS. Subgroup analyses of 138 BRCA1 and 118 triple-negative breast cancer cases showed similar results. Tumor-associated inflammation density was the strongest predictor for RFS in this series of BRCA1/2 breast cancer patients. This provides a potential risk stratification tool that can easily be implemented in routine histologic examination.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  BRCA1/2; Breast cancer; Prognostic features; Tumor-associated inflammation; Tumor-associated stroma

Mesh:

Substances:

Year:  2014        PMID: 25522926     DOI: 10.1016/j.humpath.2014.10.020

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  14 in total

Review 1.  BET bromodomain proteins and epigenetic regulation of inflammation: implications for type 2 diabetes and breast cancer.

Authors:  Dequina A Nicholas; Guillaume Andrieu; Katherine J Strissel; Barbara S Nikolajczyk; Gerald V Denis
Journal:  Cell Mol Life Sci       Date:  2016-08-04       Impact factor: 9.261

Review 2.  New Insights on COX-2 in Chronic Inflammation Driving Breast Cancer Growth and Metastasis.

Authors:  Honor J Hugo; C Saunders; R G Ramsay; E W Thompson
Journal:  J Mammary Gland Biol Neoplasia       Date:  2015-07-21       Impact factor: 2.673

3.  Genomic Signatures Predict the Immunogenicity of BRCA-Deficient Breast Cancer.

Authors:  Adam A Kraya; Kara N Maxwell; Bradley Wubbenhorst; Brandon M Wenz; John Pluta; Andrew J Rech; Liza M Dorfman; Nicole Lunceford; Amanda Barrett; Nandita Mitra; Jennifer J D Morrissette; Michael Feldman; Anupma Nayak; Susan M Domchek; Robert H Vonderheide; Katherine L Nathanson
Journal:  Clin Cancer Res       Date:  2019-03-26       Impact factor: 12.531

4.  Nomograms based on lactate dehydrogenase to albumin ratio for predicting survival in colorectal cancer.

Authors:  Yugang Hu; Yanxiang Zhou; Yinghao Cao; Hao Wang; Yuanting Yang; Riyue Jiang; Qincheng Gong; Qing Zhou
Journal:  Int J Med Sci       Date:  2022-05-29       Impact factor: 3.642

5.  Prostaglandin E2 stimulates normal bronchial epithelial cell growth through induction of c-Jun and PDK1, a kinase implicated in oncogenesis.

Authors:  Yu Fan; Ye Wang; Ke Wang
Journal:  Respir Res       Date:  2015-12-18

6.  Hormone receptor status and survival of medullary breast cancer patients. A Turkish cohort.

Authors:  Asude Aksoy; Hatice Odabas; Serap Kaya; Oktay Bozkurt; Mustafa Degirmenci; Turkan O Topcu; Aydin Aytekin; Erkan Arpaci; Nilufer Avci; Kezban N Pilanci; Havva Y Cinkir; Yakup Bozkaya; Yalcin Cirak; Mahmut Gumus
Journal:  Saudi Med J       Date:  2017-02       Impact factor: 1.484

7.  The value of neutrophil-to-lymphocyte ratio for response and prognostic effect of neoadjuvant chemotherapy in solid tumors: A systematic review and meta-analysis.

Authors:  Xuan Li; Danian Dai; Bo Chen; Hailin Tang; Xiaoming Xie; Weidong Wei
Journal:  J Cancer       Date:  2018-02-12       Impact factor: 4.207

8.  Comprehensive molecular comparison of BRCA1 hypermethylated and BRCA1 mutated triple negative breast cancers.

Authors:  Dominik Glodzik; Ana Bosch; Serena Nik-Zainal; Åke Borg; Johan Staaf; Johan Hartman; Mattias Aine; Johan Vallon-Christersson; Christel Reuterswärd; Anna Karlsson; Shamik Mitra; Emma Niméus; Karolina Holm; Jari Häkkinen; Cecilia Hegardt; Lao H Saal; Christer Larsson; Martin Malmberg; Lisa Rydén; Anna Ehinger; Niklas Loman; Anders Kvist; Hans Ehrencrona
Journal:  Nat Commun       Date:  2020-07-27       Impact factor: 14.919

9.  Breast cancer genome and transcriptome integration implicates specific mutational signatures with immune cell infiltration.

Authors:  Marcel Smid; F Germán Rodríguez-González; Anieta M Sieuwerts; Roberto Salgado; Wendy J C Prager-Van der Smissen; Michelle van der Vlugt-Daane; Anne van Galen; Serena Nik-Zainal; Johan Staaf; Arie B Brinkman; Marc J van de Vijver; Andrea L Richardson; Aquila Fatima; Kim Berentsen; Adam Butler; Sancha Martin; Helen R Davies; Reno Debets; Marion E Meijer-Van Gelder; Carolien H M van Deurzen; Gaëtan MacGrogan; Gert G G M Van den Eynden; Colin Purdie; Alastair M Thompson; Carlos Caldas; Paul N Span; Peter T Simpson; Sunil R Lakhani; Steven Van Laere; Christine Desmedt; Markus Ringnér; Stefania Tommasi; Jorunn Eyford; Annegien Broeks; Anne Vincent-Salomon; P Andrew Futreal; Stian Knappskog; Tari King; Gilles Thomas; Alain Viari; Anita Langerød; Anne-Lise Børresen-Dale; Ewan Birney; Hendrik G Stunnenberg; Mike Stratton; John A Foekens; John W M Martens
Journal:  Nat Commun       Date:  2016-09-26       Impact factor: 14.919

10.  A niche that triggers aggressiveness within BRCA1-IRIS overexpressing triple negative tumors is supported by reciprocal interactions with the microenvironment.

Authors:  Daniel Ryan; Abhilasha Sinha; Danielle Bogan; Joanna Davies; Jim Koziol; Wael M ElShamy
Journal:  Oncotarget       Date:  2017-09-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.